{"id":"W3167094271","doi":"10.1200/jco.2021.39.15_suppl.3559","title":"Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Regorafenib; TIGIT; Colorectal cancer; Oncology; Clinical endpoint; Bevacizumab; Internal medicine; Immune checkpoint; Cancer research; Cancer; Clinical trial; Immunotherapy; Nivolumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001569607,0.001495617,0.00165739,0.0003722517,0.0003440447,0.001039264,0.0008365948,0.00147119,0.006499652],"category_scores_gemma":[0.0009957374,0.0006506643,0.001535298,0.0003437197,0.001049082,0.001125471,0.0004633419,0.003264742,0.001023797],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009903895,"about_ca_system_score_gemma":0.001272824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000830502,"about_ca_topic_score_gemma":0.002609444,"domain_scores_codex":[0.999592,0.0001989069,0.00002291087,0.00007114634,0.00003127546,0.00008388429],"domain_scores_gemma":[0.9993474,0.0001183264,0.0001490346,0.00004841749,0.00003615632,0.0003007852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9461352,0.02616057,0.000929416,0.0003478265,0.0004481909,0.00004257539,0.00004925458,0.0005873081,0.006718845,0.0001319293,0.0007295205,0.01771931],"study_design_scores_gemma":[0.7253104,0.2696194,0.002121123,0.00002049182,0.0003279623,0.0000531779,0.00003015929,0.0005404697,0.0009379666,0.00014179,0.0008838793,0.00001313174],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872128,0.002081247,0.0006902001,0.0005596056,0.0003400978,0.005980488,0.001204578,0.0001153076,0.001815671],"genre_scores_gemma":[0.9860672,0.001582528,0.001685231,0.0009400995,0.0002877087,0.00524591,0.001335867,0.00002692802,0.002828499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006499652,"threshold_uncertainty_score":0.02174348,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1833079418942244,"score_gpt":0.5130975292467511,"score_spread":0.3297895873525267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}